The PROPHY-VAP Trial: Ceftriaxone to Prevent VAP in Patients with Acute Brain Injury
RebelEM
FEBRUARY 29, 2024
Discussion In patients with brain injury who required ICU admission and mechanical ventilation, the PROPHY-VAP trial found that early administration of a single dose of ceftriaxone decreased the risk of VAP, exposure to ventilation, exposure to antibiotics, prolonged ICU and hospital stay, and mortality, with no safety concerns.
122 
Let's personalize your content